Bruker Corporation develops high-performance scientific instruments and analytical and diagnostic solutions for life science, applied, biopharma, microscopy, nanoanalysis, industrial, cleantech and semiconductor metrology markets.
Recurring news for BRKR includes earnings updates for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, product launches across NMR, microbiology, infection diagnostics, spatial biology and AFM-IR spectroscopy, and governance changes. Company announcements also cover platforms such as MALDI Biotyper, IR Biotyper, MyGenius PRO, GeoMx, CellScape, CosMx and Dimension IconIR.
Bruker (BRKR) announced a research preprint describing a draft atlas of human plasma protein variants mapped using its timsTOF systems. Posted on September 28, 2026, the study by Markus Ralser at Charité and collaborators detected 179,049 proteoforms, or distinct protein forms, across 5,077 protein groups. A high-confidence map contained 44,083 proteoforms. The workflow combined intact-protein separation with mass spectrometry without nanoparticle-based enrichment.
Bruker (BRKR) introduced timsUltra AIP and timsOmni workflows for protein characterization and nucleic acid research.
MultiDIA-PASEF yielded about 350,000 peptides per sample in Parkinson’s brain samples. Analysis across complementary digests found about 14,500 protein isoforms corresponding to over 10,000 canonical proteins. ProteoScape now connects PASEF discovery with targeted validation on the same timsTOF platform, while Spectronaut v21 uses transfer learning to adapt to new acquisition modes. Guided PASEF EXciD operates at more than 30 Hz for glycopeptide characterization. Bruker also announced a co-marketing and development agreement with Affipro Analytics for integrated HDX-MS workflows. Researchers achieved complete sequence coverage of RNA and DNA oligonucleotides on timsOmni.
Bruker (BRKR) received a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center.
The investment, valued at over $6 million, includes a Bruker AV NEO-X 800 MHz spectrometer with a cryogenically cooled MAS CryoProbe, plus several additional NMR systems and upgrades for solid-state, solution-state and Dynamic Nuclear Polarization (DNP) research. The new systems are expected to be delivered in 2027 and will support chemistry, materials science, structural biology and related research at UC Berkeley and Lawrence Berkeley National Laboratory, as well as external academic, national lab and industry users via the PMRC Core NMR facility.
Bruker Corporation (BRKR)/b) plans investor presentations at three upcoming healthcare conferences in September 2026.Senior leadership will present at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 9 at 8:00 a.m. Eastern Time, the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on September 16 at 10:45 a.m. Eastern Time, and the Bank of America Global Healthcare Conference in London on September 22 at 6:45 a.m. Eastern Time. Live audio webcasts and 30-day replays will be available in the Investor Relations section of the company website.
Bruker Energy & Supercon Technologies (BEST), a segment of Bruker (BRKR), and Luvata announced a strategic collaboration to supply high‑performance RRP superconductors for next‑generation magnetic confinement fusion demonstration and power plant projects worldwide.
The partners aim to expand industrial readiness and global manufacturing capacity for RRP niobium‑tin (Nb3Sn) superconducting wires, improving supply chain flexibility and resilience for large high‑field tokamak and stellarator programs. RRP technology, designed for magnetic fields of 12–20 Tesla, is already deployed in the LHC at CERN, ultra‑high field NMR magnets, and fusion projects. BEST and Luvata have previously supported ITER and the Wendelstein 7‑X stellarator, and RRP is being evaluated by Gauss Fusion for its high‑field stellarator and GIGA fusion power plant platform.
Bruker (Nasdaq: BRKR) announced an expanded strategic collaboration with Atinary Technologies, a pioneer in Self-Driving Labs and AI-driven R&D, and made a minority investment in Atinary; financial terms were not disclosed.
The collaboration aims to integrate Atinary’s code-free SDLabs agentic AI platform with Chemspeed configurable laboratory automation, Bruker analytical instruments, and SciY scientific software into closed-loop Design-Make-Test-Analyze-Learn workflows. These integrated systems are designed to automate complex chemical experimentation, generate high-quality, reproducible, AI-ready datasets, and accelerate discovery in pharmaceuticals, chemicals, energy, and materials. Joint demonstration labs in Basel and Boston showcase workflows featuring Chemspeed robotics and Bruker benchtop NMR for small-molecule synthesis and catalysis.
Bruker (Nasdaq: BRKR) announced a majority investment in MIMETAS, a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The deal expands Bruker’s post-genomic portfolio into human physiology-relevant Microphysiological Systems (MPS), also known as New Approach Methodologies (NAMs).
MIMETAS’ offerings include the OrganoPlate organ-on-a-chip platform, OrganoReady tissue and organoid products, instruments and contract research services. Bruker plans to integrate these human model systems with its proteomics, metabolomics, NMR, preclinical imaging and spatial biology technologies. Financial terms were not disclosed, and MIMETAS will retain its brand and management.
Bruker (Nasdaq: BRKR) reported Q2 2026 revenue of $838.5 million, up 5.2% year-over-year and 2.8% organically (3.4% excluding tariff refunds). Bruker Scientific Instruments revenue was $767.3 million, up 4.7% with 2.3% organic growth, while BEST revenue rose 11.9% to $74.2 million with 8.9% organic growth.
Q2 2026 BSI bookings grew 10% organically, with book-to-bill above 1.0x. Bruker recorded a GAAP operating loss of $(65.3) million, including a non-cash goodwill impairment of $134.9 million, versus $11.9 million GAAP operating income a year ago. Non-GAAP operating income increased to $118.5 million, with margin improving to 14.1% from 9.0%.
Q2 GAAP diluted loss per share was $(0.41), while non-GAAP diluted EPS rose to $0.49 from $0.32. For the first half of 2026, revenue increased 3.9% to $1.66 billion, with non-GAAP operating margin improving to 12.2%. Bruker updated its FY 2026 outlook only for currency and tax, maintaining non-GAAP EPS guidance of $2.10–$2.15 (up 15%–17% year-over-year) on expected revenue of $3.54–$3.57 billion, implying 3%–4% reported growth and 1%–2% organic growth.
Bruker (Nasdaq: BRKR) will release its second quarter 2026 financial results before the market opens on Tuesday, August 4, 2026. A conference call and webcast to discuss results and business trends will be held at 9:00 a.m. EDT, with online, telephone, pre-registration, and replay options provided.
Bruker (Nasdaq: BRKR) has acquired the DISQVER® clinical metagenomics platform from Noscendo, expanding its NGS-based infection detection portfolio. DISQVER provides advanced bioinformatics and reporting for rapid, comprehensive whole genome sequencing (WGS) analysis directly from cell-free human blood samples without prior cultivation.
According to Bruker, the DISQVER platform can search WGS data for more than 11,000 different microbes and parasites, delivering metagenomic next-generation sequencing (mNGS) results from blood-derived cell-free DNA in less than 24 hours after sample receipt. The approach targets research applications in bloodstream infections, sepsis, endocarditis and other severe infectious diseases. Following the acquisition, DISQVER will remain for research use only while Bruker pursues diagnostic registration. Financial terms were not disclosed, and DISQVER is not expected to be material to Bruker’s FY26 financial results.